Improving Quality of Diagnostic Data
Dr. Carolyn Compton, a panelist at the upcoming 2016 Health Connect South event September 21, took time out to join me on the show to talk about the need for improving the quality of data we get through diagnostic testing through better control of how specimens are gathered, handled, and stored.
She shared an example of how a specimen, collected knowing it was positive for tumor cells, can be made to return a “Negative” result for cancer if the specimen is not handled properly once it’s been collected. She will be talking about how many factors can affect the validity and thus, value, of given tests if there exists a wide range of variance across the pre-diagnostic phase of test gathering.
A pathologist by profession, Dr. Comptom is very familiar with how significant the impact can be if diagnostic testing is unreliable due to practices that could be prevented. Insuring that we are making decisions using the best, highest quality data available, means we need to look for any areas where variability creates what in essence is data artifact.
Arizona State University ranked by US News and World Report as the most innovative university in the
country and is the #1 producer of Fulbright scholars. Mayo Clinic is ranked by US News and World Report
as the best hospital in the US. NBDA is a 501C3 dedicated to collaboratively developing and implementing the crosscutting standards needed to reengineer the biomarker development process and increase its success rate, a critical issue and limiting factor for the implementation of precision medicine.
Special Guest:
Dr. Carolyn Compton, MD
Professor Arizona State University and Mayo Clinic
CMO NBDA; CMO CASI
